BioMarin Pulls EU Hemophilia Gene Therapy Filing, But Is Not Giving Up

Agios’s MAA For Tibsovo also withdrawn

BioMarin plans to resubmit its marketing application for Roctavian to the European Medicines Agency.

Gene therapy
Several gene therapies for hemophilia are under development • Source: Shutterstock

BioMarin Pharmaceutical has withdrawn its EU marketing authorization application (MAA) for Roctavian (valoctocogene roxaparvovec), the gene therapy it is developing for severe hemophilia A that also recently suffered a setback in the US.

The company has pulled the filing because it cannot provide the data that the European Medicines Agency has asked for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography